Halozyme resumes patient enrollment and dosing in PEGPH20 clinical program
Halozyme announced it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of recombinant human hyaluronidase. July 22, 2014